New pill targets KRAS mutations in Hard-to-Treat cancers
NCT ID NCT06973564
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called JAB-23E73, taken as a pill, in adults with advanced solid tumors that have a KRAS alteration. The trial has three parts: first finding a safe dose, then optimizing it, and finally checking if the drug shrinks tumors in certain cancers like lung, colorectal, and pancreatic cancer. About 294 participants will be enrolled across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JAB-23E73 (a pan-KRAS inhibitor pill)
- What this could lead to
- If successful, this could lead to a new treatment option for people with advanced solid tumors that have a KRAS alteration, potentially shrinking tumors or slowing their growth.
- What could go wrong
- This is an early phase 1/2a trial, so the drug may not work or could have serious side effects. It is only tested in a small number of people, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Cleveland Clinic Foundation
RECRUITINGCleveland, Ohio, 44195, United States
-
Huntsman Cancer Institute
RECRUITINGSalt Lake City, Utah, 84112, United States
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
-
Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.